Navigation Links
Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance
Date:8/7/2014

may be unable to achieve expected synergies and operating efficiencies in connection with the transaction within the expected time-frames or at all and to successfully integrate the Acquired Business; the Company's and the Acquired Business' expected or targeted future financial and operating performance and results; the Company's (prior to or after the close of the Transaction) capacity to bring new products to market, including but not limited to where the Company uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an "at-risk launch"); the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings on the Company's and the Acquired Business' consolidated financial condition, results of operations or cash flows; the ability to protect the intellectual property and preserve the intellectual property rights of the Company and the Acquired Business; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the Company's business or the Acquired Business; the inherent challenges, risks and costs in the Company's ability to identify, acquire and integrate complementary or strategic acquisitions of other companies, products or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with GAAP and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with the
'/>"/>
SOURCE Mylan Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger lives ... of the world. As an engineer for the past 20 years, ... of the military service. He,s been to six of the seven ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... Iclaprim also achieved high eradication rates for ... Staphylococcus aureus (MRSA), REINACH, Switzerland, Oct. ... combined results from two pivotal Phase III,clinical ... Antimicrobial Agents,and Chemotherapy (ICAAC)/Infectious Diseases Society of ...
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 data ... aminomethylcycline (AMC). The Phase 2 study compared,safety and ... PTK 0796 to,Zyvox(R) in the treatment of patients ... trial met its primary safety and,tolerability endpoint, demonstrating ...
Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... 2014 Agein.com, the Internet’s premier anti-aging web ... of the foremost experts in the industry, is releasing its ... this winter. , “The official start of winter is still ... been hit with an icy blast. After one of the ... 2015 will usher in another brutal winter,” says Dr. Kevin ...
(Date:11/28/2014)... Brosix is always making changes to its ... a more efficient, effective, and secure experience. Most recently, ... 1. The ability to setup local servers for each ... service customers around the globe. , 2. The ability ... customers that require millions of users in one network. ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Dr. ... cosmetic dermatologists , announced the addition of Dr. Bridgit ... Nolan joins the practice after having completed her dermatology ... Medicine. , Dr. Walder invited Dr. Nolan ... in medicine, surgery and cosmetic dermatology. Not only does ...
(Date:11/28/2014)... York, New York (PRWEB) November 28, 2014 ... are continuing to move forward in New Jersey’s ... claims in a consolidated litigation established there is ... Case List updated on November 18th shows 1,293 ... was created for lawsuits that allege complications resulting ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Miami's Plastic ... website. Practice founder Dr. Jeffrey Epstein ... Created using a groundbreaking WordPress platform, the site is ... , Currently, up to 75% of all prospective ... ever, these people are logging on with smartphones, tablets, ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2
... Molecular & Cell Biology at Boston University Henry M. ... at Boston University School of Medicine discovered recently a ... expression. The study describing this work titled, "Mpk1 MAPK ... Termination," appears in the March 4 issue of ...
... new, rapid blood test that could lead to early ... thousands of people stricken with fungal meningitis, a leading ... closer to market with a recent collaboration between the ... "The ability to quickly identify yeast infection in ...
... 4 (HealthDay News) -- Children are more likely to ... playgrounds in their neighborhoods, researchers report. The study ... give their opinions about outdoor public spaces in their ... children spent watching television, using the computer and playing ...
... trial process in the United States is on shaky ... are increasingly defined by specific genetic and biologic markers ... therapies grow smaller and smaller. Coupled with skyrocketing costs ... are essential in bringing new and effective therapies to ...
... THURSDAY, March 3 (HealthDay News) -- More young people are ... engaging in same-sex encounters, according to a new report detailing ... from interviews with 13,500 men and women aged 15 to ... that more than half of young people under age 24 ...
... (HealthDay News) -- The brain,s so-called reward center actually responds ... causing fear, finds a new study in mice. The ... help explain why some people are thrill-seekers. Pleasurable or ... a bridge, can trigger the production of dopamine, a neurotransmitter ...
Cached Medicine News:Health News:Novel mechanism for control of gene expression revealed 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 3Health News:To bring effective therapies to patients quicker, use the team approach 2Health News:To bring effective therapies to patients quicker, use the team approach 3Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: